AKT1 and breast carcinoma: Upon successful validation at partner CROs (data not reported), the castPCRTM assay is currently one of the methods accepted for prospective and retrospective AKT1 E17K mutation testing of ER+ breast cancer samples for clinical trial NCT01226316.